RU2013121744A - Лечение рака/ингибирование метастазирования - Google Patents
Лечение рака/ингибирование метастазирования Download PDFInfo
- Publication number
- RU2013121744A RU2013121744A RU2013121744/15A RU2013121744A RU2013121744A RU 2013121744 A RU2013121744 A RU 2013121744A RU 2013121744/15 A RU2013121744/15 A RU 2013121744/15A RU 2013121744 A RU2013121744 A RU 2013121744A RU 2013121744 A RU2013121744 A RU 2013121744A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- reducing
- metastatic behavior
- behavior according
- preventing metastatic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 37
- 201000011510 cancer Diseases 0.000 title claims abstract 16
- 206010027476 Metastases Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000009401 metastasis Effects 0.000 title 1
- 230000008883 metastatic behaviour Effects 0.000 claims abstract 53
- 238000000034 method Methods 0.000 claims abstract 48
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims abstract 15
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims abstract 15
- 230000004899 motility Effects 0.000 claims abstract 6
- 230000005012 migration Effects 0.000 claims abstract 5
- 238000013508 migration Methods 0.000 claims abstract 5
- 230000000694 effects Effects 0.000 claims abstract 4
- 210000001519 tissue Anatomy 0.000 claims 12
- 206010006187 Breast cancer Diseases 0.000 claims 8
- 208000026310 Breast neoplasm Diseases 0.000 claims 8
- 206010060862 Prostate cancer Diseases 0.000 claims 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 8
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 claims 6
- 229960000213 ranolazine Drugs 0.000 claims 6
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 4
- 210000002469 basement membrane Anatomy 0.000 claims 4
- 229960004181 riluzole Drugs 0.000 claims 4
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 230000000431 effect on proliferation Effects 0.000 claims 2
- 230000001146 hypoxic effect Effects 0.000 claims 2
- 230000001052 transient effect Effects 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000007704 transition Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2010/001908 WO2012049440A1 (en) | 2010-10-13 | 2010-10-13 | Treatment of cancer/inhibition of metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013121744A true RU2013121744A (ru) | 2014-11-20 |
Family
ID=44022817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013121744/15A RU2013121744A (ru) | 2010-10-13 | 2010-10-13 | Лечение рака/ингибирование метастазирования |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20130203764A1 (enExample) |
| EP (4) | EP2627321A1 (enExample) |
| JP (1) | JP2013539778A (enExample) |
| KR (1) | KR20140032346A (enExample) |
| CN (2) | CN103370060A (enExample) |
| AU (2) | AU2010362412A1 (enExample) |
| BR (1) | BR112013009086A2 (enExample) |
| CA (1) | CA2851694C (enExample) |
| DK (1) | DK3132791T3 (enExample) |
| IL (1) | IL225689A0 (enExample) |
| RU (1) | RU2013121744A (enExample) |
| SG (1) | SG189352A1 (enExample) |
| WO (1) | WO2012049440A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2013121744A (ru) | 2010-10-13 | 2014-11-20 | Мустафа Билгин Али ДЖАМГОЗ | Лечение рака/ингибирование метастазирования |
| WO2013123403A1 (en) * | 2012-02-15 | 2013-08-22 | Sanford-Burnham Medical Research Institute | Theranostics platform and methods of use |
| WO2017091574A1 (en) * | 2015-11-25 | 2017-06-01 | Health Research, Inc. | Riluzole and riluzole drug combinations for the treatment of prostate cancer |
| JP6465306B2 (ja) * | 2016-02-04 | 2019-02-06 | セレックス・オンコロジー・リミテッド | 癌の治療／転移の阻害 |
| IL292302B2 (en) * | 2016-05-20 | 2023-10-01 | Biohaven Pharm Holding Co Ltd | Use of glutamate modulating factors in cancer immunotherapy |
| CN110662545A (zh) * | 2017-02-10 | 2020-01-07 | 赛立斯肿瘤学创新有限公司 | 癌症治疗和转移抑制 |
| US20200123544A1 (en) * | 2018-10-22 | 2020-04-23 | Celex Oncology Innovations Limited | Gene therapy targeting the neonatal form of nav1.5 for treating cancer |
| WO2021078987A1 (en) | 2019-10-24 | 2021-04-29 | Celex Oncology Innovations Limited | Combination treatments for cancer |
| US12624101B2 (en) | 2020-01-21 | 2026-05-12 | Celex Oncology Innovations Limited | Monoclonal antibodies against neonatal Nav1.5 |
| US20230139204A1 (en) | 2020-03-09 | 2023-05-04 | Celex Oncology Innovations Limited | Measuring electric activity of cells for the evaluation of metastatic potential of cancer cells |
| WO2022005228A1 (ko) * | 2020-07-01 | 2022-01-06 | 국립암센터 | 3-케토아실 coa 타이올레이스 억제제 및 카르니틴 아실카르니틴 운반자 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| WO2025078664A1 (en) | 2023-10-12 | 2025-04-17 | Celex Oncology Innovations Limited | Treatment of metastatic or invasive brain cancer |
| WO2025252860A1 (en) | 2024-06-04 | 2025-12-11 | Celex Oncology Innovations Limited | Ranolazine enantiomer for use in cancer treatment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1659136A (zh) * | 2002-04-18 | 2005-08-24 | 弗吉尼亚大学专利基金会 | 新的钠通道阻滞剂 |
| CA2513399A1 (en) * | 2003-01-10 | 2004-07-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
| US8835473B2 (en) * | 2004-04-16 | 2014-09-16 | Rutgers, The State University Of New Jersey | Methods and compositions for treating cancer |
| US9018222B2 (en) | 2006-03-27 | 2015-04-28 | Wex Medical Limited | Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy |
| US8394377B2 (en) * | 2008-02-21 | 2013-03-12 | The Regents Of The University Of Colorado | Methods for treating cancer using combination therapy |
| US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
| US20110251144A1 (en) * | 2008-09-16 | 2011-10-13 | Massachusetts Institute Of Technology | Molecular modulators of the wnt/beta-catenin pathway |
| RU2013121744A (ru) | 2010-10-13 | 2014-11-20 | Мустафа Билгин Али ДЖАМГОЗ | Лечение рака/ингибирование метастазирования |
-
2010
- 2010-10-13 RU RU2013121744/15A patent/RU2013121744A/ru not_active Application Discontinuation
- 2010-10-13 CN CN2010800703488A patent/CN103370060A/zh active Pending
- 2010-10-13 EP EP10776791.5A patent/EP2627321A1/en not_active Withdrawn
- 2010-10-13 AU AU2010362412A patent/AU2010362412A1/en not_active Abandoned
- 2010-10-13 US US13/879,146 patent/US20130203764A1/en not_active Abandoned
- 2010-10-13 WO PCT/GB2010/001908 patent/WO2012049440A1/en not_active Ceased
- 2010-10-13 JP JP2013533265A patent/JP2013539778A/ja active Pending
- 2010-10-13 BR BR112013009086A patent/BR112013009086A2/pt not_active IP Right Cessation
- 2010-10-13 KR KR1020137012365A patent/KR20140032346A/ko not_active Withdrawn
- 2010-10-13 CN CN202110087549.9A patent/CN112755029A/zh active Pending
- 2010-10-13 SG SG2013026968A patent/SG189352A1/en unknown
- 2010-10-13 EP EP19211429.6A patent/EP3653206A1/en not_active Ceased
- 2010-10-13 EP EP16020321.2A patent/EP3132791B1/en active Active
- 2010-10-13 CA CA2851694A patent/CA2851694C/en active Active
- 2010-10-13 EP EP25174138.5A patent/EP4640281A3/en active Pending
- 2010-10-13 DK DK16020321.2T patent/DK3132791T3/da active
-
2013
- 2013-04-10 IL IL225689A patent/IL225689A0/en unknown
-
2015
- 2015-10-13 US US14/881,952 patent/US20160096812A1/en not_active Abandoned
-
2017
- 2017-04-06 AU AU2017202267A patent/AU2017202267B2/en active Active
-
2018
- 2018-06-07 US US16/002,555 patent/US20180346431A1/en not_active Abandoned
-
2019
- 2019-09-19 US US16/576,178 patent/US11634398B2/en active Active
-
2022
- 2022-12-19 US US18/068,263 patent/US12534444B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230202994A1 (en) | 2023-06-29 |
| AU2010362412A1 (en) | 2013-05-30 |
| US11634398B2 (en) | 2023-04-25 |
| BR112013009086A2 (pt) | 2016-07-26 |
| EP4640281A2 (en) | 2025-10-29 |
| EP3132791B1 (en) | 2019-11-27 |
| WO2012049440A1 (en) | 2012-04-19 |
| EP4640281A3 (en) | 2026-01-07 |
| AU2017202267B2 (en) | 2019-01-24 |
| US20160096812A1 (en) | 2016-04-07 |
| DK3132791T3 (da) | 2020-03-09 |
| KR20140032346A (ko) | 2014-03-14 |
| IL225689A0 (en) | 2013-06-27 |
| CN112755029A (zh) | 2021-05-07 |
| US20130203764A1 (en) | 2013-08-08 |
| CA2851694C (en) | 2019-02-26 |
| EP3653206A1 (en) | 2020-05-20 |
| US12534444B2 (en) | 2026-01-27 |
| CA2851694A1 (en) | 2012-04-19 |
| US20200017457A1 (en) | 2020-01-16 |
| EP2627321A1 (en) | 2013-08-21 |
| EP3132791A1 (en) | 2017-02-22 |
| SG189352A1 (en) | 2013-05-31 |
| JP2013539778A (ja) | 2013-10-28 |
| US20180346431A1 (en) | 2018-12-06 |
| AU2017202267A1 (en) | 2017-04-27 |
| CN103370060A (zh) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dziegielewska et al. | T-type calcium channels blockers as new tools in cancer therapies | |
| EP4640281A3 (en) | Inhibition of metastasis by compounds which reduce the persistent part of the voltage-gated sodium channel | |
| Afsharimani et al. | Morphine and breast tumor metastasis: the role of matrix-degrading enzymes | |
| EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| Meng et al. | Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: experimental and clinical evidence | |
| RU2008130963A (ru) | Лечение метастатического рака молочной железы | |
| MX2020003719A (es) | Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. | |
| BRPI0409919A (pt) | combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese | |
| UY28081A1 (es) | Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celular | |
| RU2016102158A (ru) | Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака | |
| RU2016117729A (ru) | Терапия рака путем таргетинга покоящихся раковых клеток | |
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| Qu et al. | Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system | |
| Wang et al. | Effect of a rosmarinic acid supplemented hemodialysis fluid on inflammation of human vascular endothelial cells | |
| MX2025006565A (es) | Terapia contra el cancer con capivasertib y fulvestrant | |
| Damstra et al. | Cancer‐related secondary lymphoedema due to cutaneous lymphangitis carcinomatosa: clinical presentations and review of literature | |
| Lu et al. | Exploration of the effect and mechanism of activating blood circulation and stasis-removing therapy on tumor metastasis | |
| RU2013130449A (ru) | Способ комбинированного лечения рака прямой кишки | |
| CN106075454A (zh) | 一种抗肿瘤药物制剂组合 | |
| Arribas et al. | Targeting the epigenome and the cell signaling as novel therapeutic approaches for splenic marginal zone lymphoma | |
| EA200601471A1 (ru) | Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты) | |
| Solari et al. | Electrochemotherapy for cutaneous metastases: The IRCCS San Martino Hospital and National Cancer Research Institute of Genoa's experience | |
| Ahmad | Evaluating anti-oxidant potential of Callistemon viminalis leaves extracts and their compounds in STAT 3 pathway in liver cancer | |
| Cui et al. | The Crosstalk Between Epithelial-Mesenchymal Transition and Anoikis Resistance: A New Perspective of Traditional Chinese Medicine to Prevent Tumor Metastasis | |
| MIYAZAKI et al. | Clinical Appraisalof Hyperthermic Treatment Combined with Low Dose of Gemcitabine Hydrochlo Ride for the Unresectable Pancreas Cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160530 |